Physician profile
Catherine Brignoni
NPI 1114982048
$703.12
in general payments reported to CMS, 2019-2025
13 companies · $302 in 2025
The $302 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $185 · 2020: $53.35 · 2021: $33.41 · 2022: $17.68 · 2023: $38.78 · 2024: $73.17 · 2025: $302.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $414.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $414.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $168.09 | 2019 | |
| Abbvie INC. | $141.55 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $121.67 | 2025 | Austedo Xr |
| Abbott Laboratories | $73.17 | 2024 | Proclaim |
| Pfizer INC. | $42.67 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $37.55 | 2020 | |
| Catalyst Pharmaceuticals, INC. | $33.22 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.45 | 2023 | Gammagard |
| Grifols USA, LLC | $17.68 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $16.86 | 2021 | |
| Livanova USA, INC. | $15.80 | 2020 | |
| Lilly USA, LLC | $15.58 | 2019 | |
| Travere Therapeutics, INC. | $0.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Brignoni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.